SCHOTT Pharma introduces new nest design with increased number of prefillable polymer syringes

SCHOTT Pharma, a pioneer in pharmaceutical storage and administration systems, has developed a new nest for prefillable polymer syringes. It holds a total of 160 syringes with the same external dimensions, which corresponds to an increase of 60 percent compared to the standard nest with 100 syringes, conferring a benefit of higher output than with the standard nest, with the new nest from SCHOTT Pharma than with the nest with 100 syringes. This will enable drug manufacturers to increase their efficiency by up to 6 percent, significantly reduce their production costs and reduce their product carbon footprint (PCF) by 17 percent.

"With this step, we are actively using a decisive lever to reduce the costs of pharmaceutical companies and reorganize their value chain," says Andreas Reisse, CEO of SCHOTT Pharma. "With our new Nest, we enable drug manufacturers to meet their high requirements for efficiency, sustainability and regulations while maintaining high quality. We have received positive feedback from the market and the first customers are already planning to use the new product."

The new SCHOTT TOPPAC Nest 160 from SCHOTT Pharma has been specifically designed to meet these different requirements in one comprehensive solution and enable more efficient production of high-quality drugs, including vaccines, dermafillers or diluents. Due to economies of scale, the overall fixed costs are greatly reduced due to the higher output.

The Nest builds on the close collaboration between SCHOTT Pharma and Bausch + Ströbel, a leading machine manufacturer.